Literature DB >> 11012560

The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.

R M Martin1, N R Dunn, S Freemantle, S Shakir.   

Abstract

AIMS: To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England.
METHODS: In prescription-event monitoring cohort studies, data on dispensed prescriptions prescribed by general practitioners in England soon after each drug was launched were linked to subsequent clinical events recorded by the prescriber. 16 205 patients prescribed omeprazole between June 1989 and June 1990, 17 329 patients prescribed lansoprazole between May and November 1994, and 11 541 patients prescribed pantoprazole between December 1996 and June 1997 were studied.
RESULTS: The commonest adverse events in the omeprazole, lansoprazole and pantoprazole cohorts were diarrhoea (incidence: 0. 18, 0.39 and 0.23 per 1000 days of exposure, respectively); nausea/vomiting (incidence: 0.16, 0.22 and 0.18 per 1000 days of exposure, respectively); abdominal pain (incidence: 0.17, 0.21 and 0. 17 per 1000 days of exposure, respectively); and headache (incidence rates: 0.10, 0.17 and 0.15 per 1000 days of exposure, respectively). The remaining adverse events occurred at rates of less than 0.11 per 1000 days of exposure. There were little absolute differences in the rates of most events between the three proton pump inhibitors. However, diarrhoea was more commonly associated with lansoprazole compared with omeprazole (rate difference: 0.21 per 1000 days of exposure; 95% CI 0.17, 0.25; rate ratio: 2.11; 1.78, 2.51), and there was a clear age-response relationship.
CONCLUSIONS: Adverse events occurred relatively infrequently in all three cohorts. There were only small absolute differences in event rates between the three drugs, although these data suggest the hypothesis that lansoprazole is associated with more frequent occurrence of diarrhoea, particularly in the elderly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012560      PMCID: PMC2014999          DOI: 10.1046/j.1365-2125.2000.00262.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Gynecomastia during omeprazole therapy.

Authors:  L Santucci; F Farroni; S Fiorucci; A Morelli
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

Review 2.  Adverse drug reactions.

Authors:  M Pirmohamed; A M Breckenridge; N R Kitteringham; B K Park
Journal:  BMJ       Date:  1998-04-25

3.  Ocular damage associated with proton pump inhibitors.

Authors:  P S Schönhöfer; B Werner; U Tröger
Journal:  BMJ       Date:  1997-06-21

4.  Proton-pump inhibitors: three of a kind?

Authors:  D N Bateman
Journal:  Lancet       Date:  1997-06-07       Impact factor: 79.321

5.  Lethargy with omeprazole.

Authors:  E J Meeuwisse; F C Groen; A Dees; G H Smit; J P Ottervanger
Journal:  BMJ       Date:  1997-02-15

6.  What constitutes good prescribing?

Authors:  N Barber
Journal:  BMJ       Date:  1995-04-08

7.  Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study.

Authors:  K R Neal; H M Scott; R C Slack; R F Logan
Journal:  BMJ       Date:  1996-02-17

8.  Arthralgias and omeprazole.

Authors:  M Beutler; K Hartmann; M Kuhn; J Gartmann
Journal:  BMJ       Date:  1994-12-17

9.  United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals.

Authors:  M D Rawlins; D B Jefferys
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 10.  Clinical economics review: gastrointestinal disease in primary care.

Authors:  R H Jones
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

View more
  18 in total

1.  Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.

Authors:  Alfonso Carvajal; Diego Macias; Angélica Gutiérrez; Sara Ortega; María Sáinz; Luis H Martín Arias; Alfonso Velasco
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis.

Authors:  Iyad A Issa; Ola Soubra; Hania Nakkash; Lama Soubra
Journal:  Dig Dis Sci       Date:  2012-03-17       Impact factor: 3.199

3.  Population-based assessment of gastrointestinal symptoms and diseases: Cappadocia Cohort, Turkey.

Authors:  Orhan Sezgin; Hale Akpınar; Birol Özer; Murat Törüner; Kadir Bal; Serhat Bor
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

4.  Difficulties reducing inappropriate prescribing of proton pump inhibitors in the elderly.

Authors:  Emily Reeve; Michael D Wiese
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

Review 5.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 6.  Drug-induced gastrointestinal disorders.

Authors:  H L Philpott; S Nandurkar; J Lubel; P R Gibson
Journal:  Frontline Gastroenterol       Date:  2013-06-19

Review 7.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 10.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.